ArticleCancers2020

A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC.

Balazs Halmos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.